CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
靶向非霍奇金淋巴瘤中的 CAR-T 细胞耗竭：机制见解与新兴临床策略
英文原题：Targeting CAR-T cell exhaustion in non-Hodgkin lymphoma: mechanistic insights and emerging clinical strategies.
查看英文原题
Targeting CAR-T cell exhaustion in non-Hodgkin lymphoma: mechanistic insights and emerging clinical strategies.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
尽管治疗抵抗性淋巴瘤患者接受CAR-T（CAR-T）治疗的缓解率较高，但多数患者仍会复发。CAR-T 细胞耗竭是 CAR-T 治疗失败的重要原因，其特征是多种分子和表观遗传通路导致 T 细胞效应功能逐渐丧失。预防 CAR-T 细胞耗竭的策略已显示出希望，包括改造 CAR 结构、添加辅助药物以及采用不同的细胞产品制备策略。本综述讨论 CAR-T 细胞耗竭的机制及其缓解策略，以支持这一关键领域的后续研究。
展开英文摘要原文
Although the response rates to chimeric antigen receptor T (CAR-T) therapy in patients with treatment-resistant lymphoma are high, the majority of patients relapse. CAR-T cell exhaustion, characterized by the progressive loss of T-cell effector functions due to several molecular and epigenetic pathways, is a major mediator of CAR-T cell failure.
Strategies to prevent CAR-T cell exhaustion, including modifications to the CAR structure, addition of adjunctive agents, and alternative product manufacturing strategies have shown promise. In this review, we discuss the mechanisms of CAR-T cell exhaustion and describe strategies for its mitigation, with the aim of supporting further research in this critical area.
论文信息
- 作者
- Rao A、Darwish C、Campbell KS、Khanal R、Fung H、Stack A
- 第一作者单位
- Department of Medicine, Temple University Hospital, Philadelphia, PA, United States.United States
- 通讯作者单位
- Department of Bone Marrow Transplant & Cellular Therapies, Fox Chase Cancer Center, Philadelphia, PA, United States.United States
- 文献类型
- 综述
- 期刊
- Frontiers in immunology2026
- 原文标识
- PubMed 42093982 · DOI 10.3389/fimmu.2026.1727926
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →